Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 48
Filter
6.
Rev Neurol ; 71(2): 54-60, 2020 Jul 16.
Article in Spanish | MEDLINE | ID: mdl-32627160

ABSTRACT

INTRODUCTION: Although carbamazepine (CBZ) has strong enzyme-inducing properties, oxcarbazepine (OXC) and eslicarbazepine acetate (ESL) are thought to have a milder effect. These drugs are known to have effects on lipid metabolism and may cause hyponatremia and changes in blood cell counts and liver function tests. AIM: To compare the long-term effects of three antiepileptic drugs (CBZ, OXC and ESL) on these variables. PATIENTS AND METHODS: Retrospective cohort study of consecutive patients treated with CBZ, OXC or ESL. Natremia, lipid concentrations, blood cell counts and liver function tests were compared before, during and at the end of the study period. RESULTS: A total of 292 patients were included. Of these, 143 were treated with CBZ, 55 with OXC and 94 with ESL. CBZ showed a greater impact on lipid metabolism, while OXC was correlated with lower mean sodium levels and a higher frequency of hyponatremia. Lifestyle recommendations related to diet, physical activity and water intake were helpful in overcoming these side effects. No other statistically significant differences were detected. CONCLUSIONS: While CBZ showed a greater impact on lipid metabolism, OXC displayed a higher frequency of hyponatremia. Lifestyle recommendations may be helpful in overcoming these side effects. No other statistically significant differences were found.


TITLE: Efectos a largo plazo de las dibenzacepinas sobre los parámetros metabólicos: comparación retrospectiva de carbamacepina, oxcarbacepina y acetato de eslicarbacepina en el mundo real.Introducción. Aunque la carbamacepina (CBZ) tiene fuertes propiedades de inducción enzimática, se cree que la oxcarbacepina (OXC) y el acetato de eslicarbacepina (ESL) ejercen un efecto más leve. Se sabe que estos fármacos tienen efectos sobre el metabolismo lipídico, pueden causar hiponatremia y cambios en el recuento de células sanguíneas y en las pruebas de función hepática. Objetivo. Comparar los efectos a largo plazo de tres medicamentos antiepilépticos (CBZ, OXC y ESL) en estas variables. Pacientes y métodos. Estudio de cohorte retrospectivo de pacientes consecutivos tratados con CBZ, OXC o ESL. La natremia, las concentraciones de lípidos, el recuento de células sanguíneas y las pruebas de función hepática se compararon antes, durante y al final del período de estudio. Resultados. Se incluyó a 292 pacientes. De ellos, 143 fueron tratados con CBZ, 55 con OXC y 94 con ESL. La CBZ mostró un mayor impacto en el metabolismo de los lípidos, mientras que la OXC se correlacionó con niveles medios de sodio más bajos y una frecuencia mayor de hiponatremia. Las recomendaciones de estilo de vida relacionadas con la dieta, la actividad física y la ingesta de agua fueron útiles para superar estos efectos secundarios. No se detectaron otras diferencias estadísticamente significativas. Conclusiones. Mientras que la CBZ mostró un mayor impacto en el metabolismo de los lípidos, la OXC mostró una mayor frecuencia de hiponatremia. Las recomendaciones de estilo de vida pueden ser útiles para superar estos efectos secundarios. No se encontraron otras diferencias estadísticamente significativas.


Subject(s)
Anticonvulsants/pharmacology , Carbamazepine/pharmacology , Dibenzazepines/pharmacology , Metabolism/drug effects , Oxcarbazepine/pharmacology , Adult , Aged , Alanine Transaminase/blood , Anticonvulsants/adverse effects , Anticonvulsants/therapeutic use , Aspartate Aminotransferases/blood , Carbamazepine/adverse effects , Carbamazepine/therapeutic use , Dibenzazepines/adverse effects , Dibenzazepines/therapeutic use , Epilepsies, Partial/drug therapy , Epilepsies, Partial/metabolism , Female , Follow-Up Studies , Healthy Lifestyle , Humans , Hyponatremia/chemically induced , Leukocyte Count , Lipids/blood , Male , Middle Aged , Nerve Tissue Proteins/antagonists & inhibitors , Oxcarbazepine/adverse effects , Oxcarbazepine/therapeutic use , Retrospective Studies , Sodium/blood , Voltage-Gated Sodium Channels/drug effects , gamma-Glutamyltransferase/blood
7.
Nat Commun ; 10(1): 2255, 2019 05 21.
Article in English | MEDLINE | ID: mdl-31113952

ABSTRACT

Theoretical models of episodic memory have proposed that retrieval depends on interactions between the hippocampus and neocortex, where hippocampal reinstatement of item-context associations drives neocortical reinstatement of item information. Here, we simultaneously recorded intracranial EEG from hippocampus and lateral temporal cortex (LTC) of epilepsy patients who performed a virtual reality spatial navigation task. We extracted stimulus-specific representations of both item and item-context associations from the time-frequency patterns of activity in hippocampus and LTC. Our results revealed a double dissociation of representational reinstatement across time and space: an early reinstatement of item-context associations in hippocampus preceded a later reinstatement of item information in LTC. Importantly, reinstatement levels in hippocampus and LTC were correlated across trials, and the quality of LTC reinstatement was predicted by the magnitude of phase synchronization between hippocampus and LTC. These findings confirm that episodic memory retrieval in humans relies on coordinated representational interactions within a hippocampal-neocortical network.


Subject(s)
Hippocampus/physiology , Memory, Episodic , Mental Recall/physiology , Temporal Lobe/physiology , Adult , Brain Mapping/methods , Electrocorticography , Epilepsy/diagnosis , Epilepsy/physiopathology , Female , Humans , Male , Middle Aged , Nerve Net/physiology , Young Adult
8.
Encephale ; 43(1): 10-14, 2017 Feb.
Article in French | MEDLINE | ID: mdl-26796557

ABSTRACT

INTRODUCTION: Substance related disorders are more prevalent in emergency services than in the general population, about 20% of individuals in emergency care test positive for alcohol. Emergency services are strategic places to identify alcohol misuse. Attitudes to individuals presenting substance related disorders are important in developing therapeutic relationships and applying interventions. OBJECTIVE: This study explores the attitudes of an emergency staff to these individuals across a range of roles, and evolution in face of an addictology care improvement. METHOD: Data were gathered from an emergency service sample from the emergency department of a general hospital in Morlaix (France). We used a short questionnaire, adapted from previous similar French studies. RESULTS: Twenty-five persons answered the first questionnaire and 18 the second. A self-administrated attitudes questionnaire showed its interest in our study and helped us to identify attitudes and to initiate a reflection on behaviours in emergency care. Moreover, it helped to change attitudes towards individuals presenting substance related disorders. The daily setting of an addictive disorders specialized unit in emergency changed the point of view on addictive disorders of both physicians and nurses. We showed differences in addictive related disorders prevalence perception among patients attending emergency care between the two evaluations. But we also showed that physicians and nurses stressed that it was more difficult to ask patients in emergency care on the second evaluation, after and despite a daily addictive disorders specialized setting. We showed several limits in emergency staff care relationship with patients with substance related disorders. They identified difficulties to talk about addictive disorders, especially in younger and older patients. Regarding literature, we discuss our study limits and different ways of improving addictology care in emergency services.


Subject(s)
Attitude of Health Personnel , Emergency Medical Services , Substance-Related Disorders/therapy , Adult , Alcoholism/epidemiology , Emergency Medical Services/statistics & numerical data , Emergency Service, Hospital/statistics & numerical data , Female , France/epidemiology , Humans , Male , Middle Aged , Perception , Prevalence , Self Concept , Substance-Related Disorders/epidemiology , Substance-Related Disorders/psychology , Surveys and Questionnaires , Young Adult
9.
Rev. esp. med. nucl. imagen mol. (Ed. impr.) ; 34(6): 350-357, nov.-dic. 2015. tab, ilus, graf
Article in Spanish | IBECS | ID: ibc-146710

ABSTRACT

Objetivos. La SPECT de perfusión ictal-interictal, subtraction ictal SPECT coregistered to MRI (SISCOM) y 18F-FDG-PET (interictal), desempeñan un papel fundamental en la valoración prequirúrgica del paciente epiléptico fármaco-resistente. Los objetivos de este trabajo fueron establecer la reproducibilidad del análisis visual de la SPECT y SISCOM y la capacidad de la SPECT, SISCOM y PET en la identificación del foco epileptógeno. Material y métodos. Se realizó una SPECT 99mTc-HMPAO (ictal-interictal) y SISCOM (Analyze 7.0) en 47 pacientes epilépticos fármaco-resistentes (24 M, 19-60 años). En 13 pacientes se repitió el SISCOM utilizando el programa FocusDET. El análisis de las imágenes fue realizado por 2 observadores. Se valoró la reproducibilidad utilizando el índice Kappa. Los resultados conjuntos de la SPECT, SISCOM y PET, en 16 pacientes, fueron comparados con la localización del área resecada y el seguimiento clínico poscirugía (escala de Engel) o con la estereo-EEG. Resultados. Grado de acuerdo interobservador de la SPECT 91% índice Kappa 0,86. Grado de acuerdo interobservador SISCOM Analyze 7.0 82%, índice Kappa 0,80. El Analyze 7.0 mostró un elevado número de resultados no concluyentes, superior al del análisis visual. El SISCOM FocusDET mostró un grado de acuerdo interobservador 92% con un índice Kappa 0,87 y menor número de resultados no concluyentes que el Analyze. La valoración conjunta SPECT, SISCOM y PET permitió identificar 87% focos epileptógenos: 79% temporales, 26% parieto-temporales y 7% frontales. Conclusión. La SPECT ictal-interictal y el SISCOM mostraron una elevada reproducibilidad. La valoración conjunta de la SPECT ictal-interictal, SISCOM y PET permitió mejorar la rentabilidad diagnóstica de la valoración individualizada (AU)


Aims. Brain perfusion SPECT (ictal-interictal), SPECT images and subtraction ictal SPECT coregistered to MRI (SISCOM) and 18F-FDG-PET (interictal), play an important role in the pre-surgical diagnosis of patients with medically refractory epilepsy. This study aimed to establish: the reproducibility of visual ictal-interictal SPECT and SISCOM analysis altogether with the capacity of SPECT, SISCOM and PET to determine the epileptogenic zone. Material and methods. 99mTc-HMPAO SPECT ictal-interictal and SISCOM (Analyze 7.0) were performed on 47 refractory epilepsy patients (24 F, 19-60 yrs). In 13 patients, SISCOM was also performed using a new program (Focus DET). Ictal-interictal SPECT and SISCOM images were analysed independently by two nuclear medicine physicians (observer 1 and 2). Kappa concordance coefficient was used to evaluate the reproducibility. In sixteen patients, SPECT, SISCOM and PET findings were compared with the resected area during the surgery, and surgical outcome using Engel scale or with the stereo EEG-(SEEG). Results. The ictal-interictal SPECT interobserver agreement was 91%, Kappa index 0.86, SISCOM (Analyze 7.0) interobserver agreement percentage was 82%, Kappa index 0.80, Analyze 7.0 showed a higher inconclusive results than visual SPECT analysis. SISCOM FocusDET interobserver agreement was 92%, Kappa index 0.87, with lower inconclusive results than Analyze 7.0. SPECT, SISCOM and PET combined findings identified 87% seizure onset zone: 79% temporal, 26% parieto-temporal and 7% frontal. Conclusions. Ictal-interictal SPECT and SISCOM showed a high reproducibility in this sample of patients with drug-refractory epilepsy. SPECT,SISCOM and PET combined findings improved detection of epileptogenic zone in comparison with the individual assessment (AU)


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Young Adult , Epilepsy/surgery , Epilepsy , Tomography, Emission-Computed, Single-Photon/instrumentation , Tomography, Emission-Computed, Single-Photon/methods , Fluorodeoxyglucose F18 , Drug Resistance , Drug Resistance/radiation effects , Retrospective Studies , Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography/methods , Perfusion Imaging/instrumentation
10.
Epilepsy Res ; 115: 147-52, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26220393

ABSTRACT

INTRODUCTION: Older dibenzazepines with a carboxamide substitution have been demonstrated to cause deleterious effects on lipid metabolism profile, as well as frequent hyponatremia. The aim of our study is to assess the effects of eslicarbazepine acetate, a novel AED, on lipid metabolism profile, sodium values and liver function tests, as well as to compare them with previous effects of carbamazepine and oxcarbazepine. METHODS: This report describes a retrospective cohort study of 108 patients who were treated with eslicarbazepine. Of these patients, 52% had switched to eslicarbazepine from prior treatment with carbamazepine or oxcarbazepine. Laboratory values concerning lipid metabolism profile, liver function tests and sodium were assessed before and after beginning/switching treatment. Patients who began treatment or whose treatment for dyslipidemia was modified during the study period were excluded from the analysis. Co-medications that could impact lipid metabolism profile, sodium or hepatic function were kept stable during the study period. RESULTS: The mean total cholesterol of the entire group decreased significantly from prior pathological to normal values after beginning/switching treatment. The percentage of patients with pathological values decreased. Patients switching from prior carboxamides also showed significant reductions in mean LDL and triglycerides. Patients beginning treatment without prior carboxamides did not develop dyslipidemia after titration. A tendency for an increased percentage of patients with hyponatremia was detected in both groups. CONCLUSIONS: Compared with older carboxamides, eslicarbazepine acetate exhibits a safer profile related to lipid metabolism. No relevant changes were detected in liver function tests. Consequently, a vascular risk factor could be avoided in patients with chronic epilepsy, while hyponatremia still needs to be ruled out. Prospective studies are still needed.


Subject(s)
Anticonvulsants/therapeutic use , Cholesterol/blood , Dibenzazepines/therapeutic use , Epilepsy/blood , Epilepsy/drug therapy , Sodium/blood , Adult , Anticonvulsants/adverse effects , Carbamazepine/adverse effects , Carbamazepine/analogs & derivatives , Carbamazepine/therapeutic use , Dibenzazepines/adverse effects , Dyslipidemias/blood , Dyslipidemias/complications , Epilepsy/complications , Female , Humans , Liver Function Tests , Male , Outpatients , Oxcarbazepine , Retrospective Studies , Time Factors , Triglycerides/blood
11.
Rev Esp Med Nucl Imagen Mol ; 34(6): 350-7, 2015.
Article in English, Spanish | MEDLINE | ID: mdl-26118354

ABSTRACT

AIMS: Brain perfusion SPECT (ictal-interictal), SPECT images and subtraction ictal SPECT coregistered to MRI (SISCOM) and (18)F-FDG-PET (interictal), play an important role in the pre-surgical diagnosis of patients with medically refractory epilepsy. This study aimed to establish: the reproducibility of visual ictal-interictal SPECT and SISCOM analysis altogether with the capacity of SPECT, SISCOM and PET to determine the epileptogenic zone. MATERIAL AND METHODS: (99m)Tc-HMPAO SPECT ictal-interictal and SISCOM (Analyze 7.0) were performed on 47 refractory epilepsy patients (24 F, 19-60 yrs). In 13 patients, SISCOM was also performed using a new program (Focus DET). Ictal-interictal SPECT and SISCOM images were analysed independently by two nuclear medicine physicians (observer 1 and 2). Kappa concordance coefficient was used to evaluate the reproducibility. In sixteen patients, SPECT, SISCOM and PET findings were compared with the resected area during the surgery, and surgical outcome using Engel scale or with the stereo EEG-(SEEG). RESULTS: The ictal-interictal SPECT interobserver agreement was 91%, Kappa index 0.86, SISCOM (Analyze 7.0) interobserver agreement percentage was 82%, Kappa index 0.80, Analyze 7.0 showed a higher inconclusive results than visual SPECT analysis. SISCOM FocusDET interobserver agreement was 92%, Kappa index 0.87, with lower inconclusive results than Analyze 7.0. SPECT, SISCOM and PET combined findings identified 87% seizure onset zone: 79% temporal, 26% parieto-temporal and 7% frontal. CONCLUSIONS: Ictal-interictal SPECT and SISCOM showed a high reproducibility in this sample of patients with drug-refractory epilepsy. SPECT,SISCOM and PET combined findings improved detection of epileptogenic zone in comparison with the individual assessment.


Subject(s)
Drug Resistant Epilepsy/diagnostic imaging , Magnetic Resonance Imaging/methods , Multimodal Imaging/methods , Neuroimaging/methods , Perfusion Imaging/methods , Positron-Emission Tomography/methods , Tomography, Emission-Computed, Single-Photon/methods , Adult , Anticonvulsants/therapeutic use , Cerebrovascular Circulation , Drug Resistance , Drug Resistant Epilepsy/drug therapy , Drug Resistant Epilepsy/surgery , Electroencephalography/methods , Female , Fluorine Radioisotopes , Fluorodeoxyglucose F18 , Humans , Male , Middle Aged , Observer Variation , Radiopharmaceuticals , Reproducibility of Results , Retrospective Studies , Subtraction Technique , Technetium Tc 99m Exametazime
12.
Clin Genet ; 88(1): 41-8, 2015 Jul.
Article in English | MEDLINE | ID: mdl-24916970

ABSTRACT

We report the analysis of altogether 1050 suspected hereditary breast/ovarian cancer (HBOC) families, 524 fully screened for BRCA1/BRCA2 mutations and 526 tested only for the most common mutations. Of the 119 families with pathogenic mutations, 40 (33.6%) had the BRCA2 c.156_157insAlu rearrangement and 15 (12.6%) the BRCA1 c.3331_3334del mutation, the former being specific of Portuguese ancestry and the latter showing a founder effect in Portugal. Interestingly, the two most common mutations were found in a significant proportion of the HBOC families with an a priori BRCAPRO mutation probability <10%. We recommend that all suspected HBOC families from Portugal or with Portuguese ancestry, even those fulfilling moderately stringent clinical-criteria for genetic testing, should be specifically analyzed for the two most common BRCA1/BRCA2 founder mutations, and we here present a simple method for this first tier test. Screening of the entire coding regions of BRCA1 and BRCA2 should subsequently be offered to those families with a mutation probability ≥10% if none of those founder mutations are found.


Subject(s)
Genes, BRCA1 , Genes, BRCA2 , Genetic Testing , Hereditary Breast and Ovarian Cancer Syndrome/genetics , Mutation , Adult , Female , Founder Effect , Genetic Predisposition to Disease , Humans , Male , Middle Aged , Portugal , White People/genetics
13.
Neurología (Barc., Ed. impr.) ; 29(2): 94-101, mar. 2014. tab, graf
Article in Spanish | IBECS | ID: ibc-119451

ABSTRACT

Introducción: La eslicarbazepina (ESL) es un nuevo fármaco antiepileptico (FAE) analogo de la carbamazepina (CBZ) y la oxcarbazepina (OXC). Analizamos su respuesta terapeutica inicial y el paso desde CBZ y OXC. Métodos: Evaluamos en un estudio transversal a 61 pacientes con un amplio espectro de epilepsias farmacorresistentes. El cambio desde CBZ y OXC se realizo en una noche con una equivalencia de 1:1,3 y 1:1 mg. Resultados: La epilepsia mas frecuente fue la de lobulo temporal (62,3%). La etiología más frecuente la esclerosis mesial (26,2%). El seguimiento medio fue de 4,7 ± 3,2 meses. En 40 pacientes con seguimiento mínimo de 3 meses, la frecuencia mediana de crisis se redujo un 63,6% (p < 0,001), siendo en un 30% la reducción ≥ 80%. Los efectos adversos (EA) aparecieron en el 54,3% siempre durante la fase de titulación, siendo mas frecuentes a dosis superiores a 800 mg (73,9% vs. 47,4%; p = 0,042) y el mas importante el mareo (34,4%), siendo mas habitual en asociación con VPA, LTG y/o LCS (19,2% vs. 45,7%; p = 0,031). La tasa de retención temprana a los 3 meses fue del 75,4%. En 25 pacientes se cambio desde CBZ o OXC, siendo los EA transitorios (69,2% y 33%; p = 0,073). Pasados 3 meses del cambio, la frecuencia mediana de crisis había disminuido un 20% (p < 0,075). Conclusiones: La ESL es eficaz en el tratamiento de epilepsias focales, con una tasa de retención temprana > 70%. Los EA tienen lugar durante la fase de titulación y según los fármacos antiepilépticos asociados. El cambio rapido desde CBZ y OXC puede realizarse de forma segura


Introduction: Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED) and an analogue to carbamazepine (CBZ) and oxcarbazepine (OXC). In this study, we evaluate initial therapeutic response to ESL and events in the change from CBZ and OXC. Methods: We evaluated 61 patients with a broad spectrum of drug-resistant epilepsies in a cross-sectional study. The switch from CBZ and OXC to ESL was carried out in a single night at ratios of 1:1.3 and 1:1 mg respectively. Results: The most common form of epilepsy was temporal lobe epilepsy (62.3%). The most common aetiology was mesial temporal sclerosis (26.2%). Mean follow-up time was 4.7±3.2 months. In 40 patients with a minimum follow-up period of 3 months, monthly median seizure frequency dropped by 63.6% (P<.001) and a reduction of 80% or more was recorded in 30%. Adverse events (AEs) occurred in 54%; all appeared during the titration phase. They were more frequent at doses in excess of 800 mg (73.9% vs. 47.4%; P=.042). The most common AE was dizziness (34.4%), which was commonly associated with VPA, LTG and/or LCS consumption (19.2% vs. 45.7%; P=.031). The retention rate at 3 months was 75.4%. A total of 25 patients replaced CBZ or OXC treatment with ESL; any AEs were transient (69.2% for CBZ and 33% for OXC; P=.073). At 3 months after the treatment change, median seizure frequency had decreased by 20% (P<.075). Conclusions: ESL is effective in the treatment of focal epilepsies and its early retention rate is > 70%. AEs occurred during the titration phase and corresponded to associated AEDs. A rapid change from CBZ and OXC to ESL treatment can be safely performed


Subject(s)
Humans , Epilepsy/drug therapy , Anticonvulsants/therapeutic use , Drug Approval , Drug Resistance , Carbamazepine/therapeutic use
14.
Neurologia ; 29(2): 94-101, 2014 Mar.
Article in English, Spanish | MEDLINE | ID: mdl-23623701

ABSTRACT

INTRODUCTION: Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED) and an analogue to carbamazepine (CBZ) and oxcarbazepine (OXC). In this study, we evaluate initial therapeutic response to ESL and events in the change from CBZ and OXC. METHODS: We evaluated 61 patients with a broad spectrum of drug-resistant epilepsies in a cross-sectional study. The switch from CBZ and OXC to ESL was carried out in a single night at ratios of 1:1.3 and 1:1mg respectively. RESULTS: The most common form of epilepsy was temporal lobe epilepsy (62.3%). The most common aetiology was mesial temporal sclerosis (26.2%). Mean follow-up time was 4.7±3.2 months. In 40 patients with a minimum follow-up period of 3 months, monthly median seizure frequency dropped by 63.6% (P<.001) and a reduction of 80% or more was recorded in 30%. Adverse events (AEs) occurred in 54%; all appeared during the titration phase. They were more frequent at doses in excess of 800mg (73.9% vs. 47.4%; P=.042). The most common AE was dizziness (34.4%), which was commonly associated with VPA, LTG and/or LCS consumption (19.2% vs. 45.7%; P=.031). The retention rate at 3 months was 75.4%. A total of 25 patients replaced CBZ or OXC treatment with ESL; any AEs were transient (69.2% for CBZ and 33% for OXC; P=.073). At 3 months after the treatment change, median seizure frequency had decreased by 20% (P<.075). CONCLUSIONS: ESL is effective in the treatment of focal epilepsies and its early retention rate is > 70%. AEs occurred during the titration phase and corresponded to associated AEDs. A rapid change from CBZ and OXC to ESL treatment can be safely performed.


Subject(s)
Anticonvulsants/therapeutic use , Dibenzazepines/therapeutic use , Epilepsy/drug therapy , Adult , Cross-Sectional Studies , Drug Resistance , Female , Humans , Male , Middle Aged
15.
J Appl Microbiol ; 112(1): 159-74, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22017648

ABSTRACT

AIMS: This work was conducted to identify the antifungal compounds produced by two previously isolated Bacillus sp. strains: ARP(2) 3 and MEP(2) 18. Both strains were subjected to further analysis to determine their taxonomic position and to identify the compounds responsible for their antifungal activity as well as to evaluate the efficiency of these strains to control sclerotinia stem rot in soybean. METHODS AND RESULTS: The antifungal compounds were isolated by acid precipitation of cell-free supernatants, purified by RP-HPLC and then tested for antagonistic activity against Sclerotinia sclerotiorum. Mass spectra from RP-HPLC eluted fractions showed the presence of surfactin C(15) , fengycins A (C(16) -C(17)) and B (C(16)) isoforms in supernatants from strain ARP(2) 3 cultures, whereas the major lipopeptide produced by strain MEP(2) 18 was iturin A C(15) . Alterations in mycelial morphology and sclerotial germination were observed in the presence of lipopeptides-containing supernatants from Bacillus strains cultures. Foliar application of Bacillus amyloliquefaciens strains on soybean plants prior to S. sclerotiorum infection resulted in significant protection against sclerotinia stem rot compared with noninoculated plants or plants inoculated with a nonlipopeptide-producing B. subtilis strain. CONCLUSIONS: Both strains, renamed as B. amyloliquefaciens ARP(2) 3 and MEP(2) 18, were able to produce antifungal compounds belonging to the cyclic lipopeptide family. Our data suggest that the foliar application of lipopeptide-producing B. amyloliquefaciens strains could be a promising strategy for the management of sclerotinia stem rot in soybean. SIGNIFICANCE AND IMPACT OF THE STUDY: Sclerotinia stem rot was ranked as one of the most severe soybean disease in Argentina and worldwide. The results of this study showed the potential of B. amyloliquefaciens strains ARP(2) 3 and MEP(2) 18 to control plant diseases caused by S. sclerotiorum.


Subject(s)
Ascomycota/physiology , Bacillus/metabolism , Biological Control Agents , Glycine max/microbiology , Lipopeptides/biosynthesis , Lipopeptides/metabolism , Plant Diseases , Animals , Antifungal Agents/metabolism , Argentina , Bacillus/chemistry , Bacillus/classification , Bacillus/enzymology , Lipopeptides/chemistry , Peptides, Cyclic/biosynthesis , Peptides, Cyclic/isolation & purification , Plant Diseases/microbiology , Plant Diseases/prevention & control
16.
Braz. j. med. biol. res ; 43(7): 677-680, July 2010. graf, tab
Article in English | LILACS | ID: lil-550738

ABSTRACT

A 3-bp insertion/deletion polymorphism in intron 6 of GSTM3 (rs1799735, GSTM3*A/*B) affects the activity of the phase 2 xenobiotic metabolizing enzyme GSTM3 and has been associated with increased cancer risk. The GSTM3*B allele is rare or absent in Southeast Asians, occurs in 5-20 percent of Europeans but was detected in 80 percent of Bantu from South Africa. The wide genetic diversity among Africans led us to investigate whether the high frequency of GSTM3*B prevailed in other sub-Saharan African populations. In 168 healthy individuals from Angola, Mozambique and the São Tomé e Príncipe islands, the GSTM3*B allele was three times more frequent (0.74-0.78) than the GSTM3*A allele (0.22-0.26), with no significant differences in allele frequency across the three groups. We combined these data with previously published results to carry out a multidimensional scaling analysis, which provided a visualization of the worldwide population affinities based on the GSTM3 *A/*B polymorphism.


Subject(s)
Female , Humans , Male , Gene Frequency/genetics , Glutathione Transferase/genetics , Polymorphism, Genetic/genetics , Africa South of the Sahara , Genotype , Polymorphism, Restriction Fragment Length
17.
Braz J Med Biol Res ; 43(7): 677-80, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20549140

ABSTRACT

A 3-bp insertion/deletion polymorphism in intron 6 of GSTM3 (rs1799735, GSTM3*A/*B) affects the activity of the phase 2 xenobiotic metabolizing enzyme GSTM3 and has been associated with increased cancer risk. The GSTM3*B allele is rare or absent in Southeast Asians, occurs in 5-20% of Europeans but was detected in 80% of Bantu from South Africa. The wide genetic diversity among Africans led us to investigate whether the high frequency of GSTM3*B prevailed in other sub-Saharan African populations. In 168 healthy individuals from Angola, Mozambique and the São Tomé e Príncipe islands, the GSTM3*B allele was three times more frequent (0.74-0.78) than the GSTM3*A allele (0.22-0.26), with no significant differences in allele frequency across the three groups. We combined these data with previously published results to carry out a multidimensional scaling analysis, which provided a visualization of the worldwide population affinities based on the GSTM3 *A/*B polymorphism.


Subject(s)
Gene Frequency/genetics , Glutathione Transferase/genetics , Polymorphism, Genetic/genetics , Africa South of the Sahara , Female , Genotype , Humans , Male , Polymorphism, Restriction Fragment Length
18.
Gut ; 58(8): 1135-43, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19282305

ABSTRACT

BACKGROUND/AIM: Endotoxaemia can complicate hepatic ischaemia-reperfusion (IR) injury. Endocannabinoids appear to modulate the haemodynamic alterations and cytokine response induced by lipopolysaccharide (LPS). Thus, we aimed to determine the effect of the endocannabinoid CB1-receptor antagonist Rimonabant in a model of hepatic IR injury complicated by endotoxaemia. METHODS: Sprague-Dawley rats pre-treated with Rimonabant 3 or 10 mg/kg or vehicle underwent partial hepatic IR and lipopolysaccharide (LPS) injection at reperfusion. Liver injury was evaluated by serum alanine aminotransferase (ALT) and necrotic-cell count. The inflammatory response was investigated by assessing hepatic neutrophil infiltration, tumour necrosis factor alpha (TNFalpha), interferon gamma (IFNgamma), interleukin 6 (IL6), and suppressor of cytokine signalling (SOCS) 1 and SOCS3 gene expression by real-time polymerase chain reaction (RT-PCR). Systolic blood pressure and hepatic blood flow were measured as haemodynamic parameters. Finally, lipid peroxidation, glutathione status, and immunoreactive CB1 receptor expression in the liver were also determined. RESULTS: Liver injury and neutrophil infiltration occurring in the late-phase of LPS-enhanced IR were significantly reduced by CB1-receptor antagonism. Rimonabant-treated rats showed significantly higher gene expression of IFNgamma, IL6, SOCS1 and SOCS3 in "early" reperfusion, while that of TNFalpha was reduced. These findings were associated with increased STAT3 phosphorylation. Furthermore, CB1-receptor antagonism significantly improved the oxidative injury and haemodynamic alterations occurring during reperfusion in untreated rats. Finally, CB1-receptor immunoreactivity was upregulated early after reperfusion. CONCLUSIONS: This study demonstrates that CB1-receptor antagonism protects the liver against LPS-enhanced IR injury by interfering with the inflammatory response that causes the late, neutrophil-dependent phase of reperfusion injury, although the prevention of the transient endotoxin-related hypotension occurring early during reperfusion may be also involved.


Subject(s)
Endotoxemia/etiology , Liver/blood supply , Piperidines/therapeutic use , Pyrazoles/therapeutic use , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Reperfusion Injury/prevention & control , Alanine Transaminase/blood , Animals , Blood Pressure/drug effects , Drug Evaluation, Preclinical , Lipopolysaccharides , Liver/metabolism , Liver/pathology , Liver Circulation/drug effects , Male , Necrosis , Neutrophil Infiltration , Rats , Rats, Sprague-Dawley , Receptor, Cannabinoid, CB1/metabolism , Reperfusion Injury/complications , Reperfusion Injury/metabolism , Rimonabant
19.
Dig Liver Dis ; 39(10): 943-51, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17692581

ABSTRACT

BACKGROUND/AIM: Controversial experimental observations suggest that granulocyte colony stimulating-factor may promote hepatic regeneration after hepatectomy and chemical injury either by directly stimulating adult liver cells or facilitating the mobilization of bone marrow cells and their homing to the liver. We investigated whether different schedules of granulocyte colony stimulating-factor administration protect against experimental acute liver injury. METHODS: Acute liver injury was induced in Sprague-Dawley fed rats by injecting a single intraperitoneal dose of carbon tetrachloride. Recombinant human granulocyte colony stimulating-factor or vehicle was given daily after intoxication (4 days) or before (7 days) and after carbon tetrachloride administration. Liver injury and regeneration were assessed 2 and 4 days after damage. Bone marrow cells mobilization was evaluated by the white blood cell count and the assessment of circulating clonogenic haematopoietic progenitors (colony forming unit-cells). RESULTS: In this experimental model, although granulocyte colony stimulating-factor induced the significant mobilization of colony forming unit-cells, the study cytokine had no effect on liver injury (serum alanine amino transaminase level and necrotic index) and liver regeneration (mitotic index and bromodeoxyuridine incorporation), regardless of the administration schedule. CONCLUSIONS: This study does not support the conclusion that: (1) granulocyte colony stimulating-factor exerts a protective effect against toxic-induced, non-lethal acute liver injury and (2) promotes hepatocyte regeneration.


Subject(s)
Colony-Stimulating Factors/therapeutic use , Liver Failure, Acute/drug therapy , Animals , Carbon Tetrachloride/toxicity , Disease Models, Animal , Image Cytometry , Immunohistochemistry , Leukocyte Count , Liver Failure, Acute/chemically induced , Liver Failure, Acute/pathology , Liver Regeneration/drug effects , Male , Rats , Rats, Sprague-Dawley , Recombinant Proteins , Treatment Outcome
20.
Dig Liver Dis ; 37(9): 689-97, 2005 Sep.
Article in English | MEDLINE | ID: mdl-15935746

ABSTRACT

BACKGROUND AND AIMS: Oxidative stress contributes to ischemia-reperfusion injury in fatty livers. This study aimed to determine whether glycogen depletion influences this oxidative injury and whether the administration of glucose can be protective. METHODS: Rats with choline deficiency-induced fatty liver underwent hepatic ischemia-reperfusion. Experimental groups: (1) fed rats; (2) 18 h fasted rats; (3) 18 h fasted rats supplemented with glucose prior to surgery. The thiobarbituric acid-reactive substances, protein carbonyls and total glutathione concentrations were measured in liver tissue and isolated mitochondria as parameters of oxidative stress before and after ischemia and during reperfusion. The mitochondrial F1-ATPase content and the serum alanine transaminase were also determined. RESULTS: With respect to fed rats, fasted rats exhibited an increased oxidative injury in both liver tissue and isolated mitochondria throughout the experiment with the only exception of thiobarbituric acid-reactive substances, which were not affected by the nutritional status in liver tissue. Fasted rats showed a significantly lower F1-ATPase content and higher alanine transaminase levels. Glucose supplementation significantly reduced the fasting-associated exacerbation of oxidative stress and liver injury and the F1-ATPase exhaustion. CONCLUSIONS: These data indicate that the pre-existing hepatic glycogen content modulates the oxidative damage in rat fatty livers exposed to ischemia-reperfusion injury and that the energetic substrate supplementation may represent a clinically feasible protective strategy.


Subject(s)
Fatty Liver/pathology , Glucose/pharmacology , Oxidative Stress/physiology , Reperfusion Injury/physiopathology , Alanine Transaminase/blood , Alanine Transaminase/metabolism , Animals , Dietary Supplements , Fatty Liver/metabolism , Glucose/administration & dosage , Glutathione/metabolism , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Nutritional Status , Oxidative Stress/drug effects , Protein Carbonylation , Proton-Translocating ATPases/metabolism , Rats , Rats, Sprague-Dawley , Reperfusion Injury/prevention & control , Thiobarbituric Acid Reactive Substances/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...